There are a number of disease areas where pharmacogenomics has been shown to improve the way new medicines are developed and made available to patients. These include cancer, dementia and arthritis, and these diseases will be important areas for us. In addition, pharmacogenomics will be valuable in diseases where genetic variation plays a significant role in determining the risk to an individual, such as diabetes or heart disease. We are also particularly interested in applying the approach to less common diseases which are strongly influenced by genetics, such as muscular dystrophies, and Huntingdon's disease. Patients with these diseases, many of which affect young children, would really benefit from new treatments, and we are keen to apply our expertise in these areas.